Chen Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chen Zhou has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Xunming Ji
Capital Medical University
23 shared publications Huimin Jiang
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Ministry of Science and Technology, Capital Medical University, Beijing, China
17 shared publicationsYifan Zhou
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Ministry of Science and Technology, Capital Medical University, Beijing, China
17 shared publicationsLu Liu
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
13 shared publicationsHuimin Wei
Beijing Advanced Innovation Center for Big Data‐Based Precision Medicine School of Biological Science and Medical Engineering, Beihang University Beijing China
10 shared publicationsHui Li
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
8 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Elsevier in The Lancet Digital Health
- Vol. 8 (6) , 100989
Ischaemic stroke recurrence in patients with symptomatic intracranial atherosclerotic stenosis in China (PROMISE): a multivariable prediction model development and validation study
- 21 April 2026
- Published by Elsevier in The Lancet Digital Health
- Vol. 8 (6) , 100989
Open AccessIschaemic stroke recurrence in patients with symptomatic intracranial atherosclerotic stenosis in China (PROMISE): a multivariable prediction model development and validation study
- Open Access
- 20 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Efficacy and safety of albumin combined with endovascular therapy in the treatment of patients with acute ischemic stroke: a randomized clinical trial
The safety and efficacy of albumin combined with endovascular therapy for participants with acute ischemic stroke is unknown. This randomized, double blinded, multicenter study was conducted in China and completed in 2025. Eligible participants were randomly assigned in a 1:1 ratio to albumin group (0.5 g/kg; maximum dose 150 mL; intravenously infusion once daily for 4 days) or placebo group (equivalent volume of placebo). The primary endpoint was the change in infarct volume from baseline to day 5. A total of 134 patients were randomized (66 in albumin group and 68 in placebo group) and 134 patients were included in the final analysis. Albumin reduced infarct volume growth from baseline to day 5 compared with placebo (median growth 7.5 mL vs 16.5 mL, adjusted median difference −8.63, 95%CI (−13.85 to −5.07); P = 0.003). The safety outcomes did not differ between the two groups. This work suggests that albumin plus endovascular therapy could significantly reduce infarct volume growth compared with the placebo group, without raising safety concerns. (Funded by the National Natural Science Foundation of China and others; ClinicalTrials.gov registration: NCT06538844.)
- 20 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessEfficacy and safety of albumin combined with endovascular therapy in the treatment of patients with acute ischemic stroke: a randomized clinical trial
The safety and efficacy of albumin combined with endovascular therapy for participants with acute ischemic stroke is unknown. This randomized, double blinded, multicenter study was conducted in China and completed in 2025. Eligible participants were randomly assigned in a 1:1 ratio to albumin group (0.5 g/kg; maximum dose 150 mL; intravenously infusion once daily for 4 days) or placebo group (equivalent volume of placebo). The primary endpoint was the change in infarct volume from baseline to day 5. A total of 134 patients were randomized (66 in albumin group and 68 in placebo group) and 134 patients were included in the final analysis. Albumin reduced infarct volume growth from baseline to day 5 compared with placebo (median growth 7.5 mL vs 16.5 mL, adjusted median difference −8.63, 95%CI (−13.85 to −5.07); P = 0.003). The safety outcomes did not differ between the two groups. This work suggests that albumin plus endovascular therapy could significantly reduce infarct volume growth compared with the placebo group, without raising safety concerns. (Funded by the National Natural Science Foundation of China and others; ClinicalTrials.gov registration: NCT06538844.)
- Open Access
- 9 April 2026
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 20 (2) , 72
Cerebral blood flow alterations in non-auditory tinnitus: implications for cerebral venous congestion pathophysiology
Background Cerebral venous congestion (CVC), including internal jugular vein stenosis (IJVS) and cerebral venous sinus stenosis (CVSS), can impair venous drainage, leading to secondary reductions in cerebral blood flow (CBF) and neurological symptoms such as non-auditory tinnitus (NAT). While arterial spin labeling (ASL) primarily measures arterial perfusion, it also provides insights into global perfusion changes in venous pathologies. This study investigates CBF alterations in CVC patients, particularly those with NAT. Methods A cross-sectional study was conducted with 87 participants, including 34 NAT+ patients, 17 NAT- patients, and 36 healthy controls (HC). Multi-delay pseudo-continuous ASL was used to quantify whole-brain and regional CBF based on the anatomical automatic labeling atlas version 3 (AAL3v1), adjusted for arterial transit time. Group differences in CBF were assessed, and correlations with clinical variables were analyzed, including tinnitus duration, sleep quality, anxiety, depression, and cognitive function. Results Patients in the NAT+ group exhibited significant CBF reductions in the left hemisphere, cerebrum, and specific regions, including the insula, paracentral lobule, and precentral gyrus, compared to those in the NAT- and HC groups. Reduced CBF in NAT+ patients was correlated with longer tinnitus duration, poorer sleep quality, and worse depression scores. Further analysis revealed that the affected regions were part of the attention, sensorimotor, default mode, and cerebellar networks. Conclusion This study identified a distinct pattern of cerebral perfusion alterations in patients with CVC, particularly those with NAT. The findings highlight characteristic regional reductions in CBF associated with impaired venous outflow, offering new insights into the venous pathophysiological mechanisms underlying NAT. Moreover, reduced CBF was found to be associated with clinical symptoms such as sleep disturbances and emotional dysregulation. These findings support a link between venous pathology and altered cerebral perfusion patterns with symptom correlations, warranting confirmation in larger and longitudinal cohorts.
- 9 April 2026
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 20 (2) , 72
Open AccessCerebral blood flow alterations in non-auditory tinnitus: implications for cerebral venous congestion pathophysiology
Background Cerebral venous congestion (CVC), including internal jugular vein stenosis (IJVS) and cerebral venous sinus stenosis (CVSS), can impair venous drainage, leading to secondary reductions in cerebral blood flow (CBF) and neurological symptoms such as non-auditory tinnitus (NAT). While arterial spin labeling (ASL) primarily measures arterial perfusion, it also provides insights into global perfusion changes in venous pathologies. This study investigates CBF alterations in CVC patients, particularly those with NAT. Methods A cross-sectional study was conducted with 87 participants, including 34 NAT+ patients, 17 NAT- patients, and 36 healthy controls (HC). Multi-delay pseudo-continuous ASL was used to quantify whole-brain and regional CBF based on the anatomical automatic labeling atlas version 3 (AAL3v1), adjusted for arterial transit time. Group differences in CBF were assessed, and correlations with clinical variables were analyzed, including tinnitus duration, sleep quality, anxiety, depression, and cognitive function. Results Patients in the NAT+ group exhibited significant CBF reductions in the left hemisphere, cerebrum, and specific regions, including the insula, paracentral lobule, and precentral gyrus, compared to those in the NAT- and HC groups. Reduced CBF in NAT+ patients was correlated with longer tinnitus duration, poorer sleep quality, and worse depression scores. Further analysis revealed that the affected regions were part of the attention, sensorimotor, default mode, and cerebellar networks. Conclusion This study identified a distinct pattern of cerebral perfusion alterations in patients with CVC, particularly those with NAT. The findings highlight characteristic regional reductions in CBF associated with impaired venous outflow, offering new insights into the venous pathophysiological mechanisms underlying NAT. Moreover, reduced CBF was found to be associated with clinical symptoms such as sleep disturbances and emotional dysregulation. These findings support a link between venous pathology and altered cerebral perfusion patterns with symptom correlations, warranting confirmation in larger and longitudinal cohorts.
- Open Access
- 24 March 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1681287
Case Report: Unveiling segmental hemodynamic heterogeneity in internal jugular vein stenosis: a patient-specific CFD analysis
Background and purpose: While non-thrombotic internal jugular vein stenosis (IJVS), predominantly from extrinsic compression, is increasingly linked to cerebral venous outflow insufficiency, its segment-specific pathophysiology remains unclear. Given the distinct J1-J3 anatomy of the internal jugular vein, segment-based characterization may aid management. Case presentation: We retrospectively analyzed five patients with non-thrombotic IJVS affecting different segments and etiologies. Clinical features, segment involvement, and lesion morphology were recorded. Patient-specific hemodynamics were modeled with computational fluid dynamics (CFD) from head-neck CT venography (CTV) using identical boundary conditions for cross-case comparison. All cases showed trans-stenotic pressure gradients that increased with stenosis severity. Elevated wall shear stress localized to the stenosis, with high-velocity jets within the narrowed segment and downstream vortices in post-stenotic regions. J3 stenoses from C1 transverse process and/or styloid compression improved after decompression, with better hemodynamic metrics, venous morphology, and symptoms. J1-J2 stenoses were mainly due to soft-tissue or arterial compression; feasible interventions were limited and conservative care yielded modest benefit. Conclusions: IJVS demonstrates segment-specific morphological and hemodynamic patterns. Patient-specific CFD derived from CTV quantitatively characterizes these abnormalities and may inform treatment selection and prognosis, although validation in larger cohorts is warranted.
- 24 March 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1681287
Open AccessCase Report: Unveiling segmental hemodynamic heterogeneity in internal jugular vein stenosis: a patient-specific CFD analysis
Background and purpose: While non-thrombotic internal jugular vein stenosis (IJVS), predominantly from extrinsic compression, is increasingly linked to cerebral venous outflow insufficiency, its segment-specific pathophysiology remains unclear. Given the distinct J1-J3 anatomy of the internal jugular vein, segment-based characterization may aid management. Case presentation: We retrospectively analyzed five patients with non-thrombotic IJVS affecting different segments and etiologies. Clinical features, segment involvement, and lesion morphology were recorded. Patient-specific hemodynamics were modeled with computational fluid dynamics (CFD) from head-neck CT venography (CTV) using identical boundary conditions for cross-case comparison. All cases showed trans-stenotic pressure gradients that increased with stenosis severity. Elevated wall shear stress localized to the stenosis, with high-velocity jets within the narrowed segment and downstream vortices in post-stenotic regions. J3 stenoses from C1 transverse process and/or styloid compression improved after decompression, with better hemodynamic metrics, venous morphology, and symptoms. J1-J2 stenoses were mainly due to soft-tissue or arterial compression; feasible interventions were limited and conservative care yielded modest benefit. Conclusions: IJVS demonstrates segment-specific morphological and hemodynamic patterns. Patient-specific CFD derived from CTV quantitatively characterizes these abnormalities and may inform treatment selection and prognosis, although validation in larger cohorts is warranted.
- Open Access
- 23 March 2026
- Published by Wolters Kluwer Health in Brain Circulation
- Vol. 12 (4) , 362-377
Rethinking the diagnostic criteria for cerebral venous outflow insufficiency: Is elevated intracranial pressure essential? A narrative review
The relationship between intracranial hypertension (IH) and cerebral venous outflow insufficiency (CVOI), including cerebral venous sinus stenosis (CVSS) and internal jugular vein stenosis (IJVS), remains controversial. Although elevated intracranial pressure (ICP) is often regarded as a hallmark of CVOI, recent evidence indicates that a subset of patients with radiologically confirmed CVSS or IJVS exhibit normal or only mildly elevated ICP (< 250 mmH 2 O). This challenges the notion that ICP elevation is essential for diagnosis and raises concern about misdiagnosis when relying solely on ICP thresholds. This review summarizes the clinical features, imaging findings, and hemodynamic characteristics of CVOI and examines the bidirectional relationship between CVOI and ICP. Possible mechanisms for normal ICP include preserved lymphatic cerebrospinal fluid drainage, collateral venous pathways, and anatomical variation. Moreover, persistent ICP elevation may itself cause secondary venous collapse, creating a feedback loop. These findings suggest that ICP elevation is neither necessary nor sufficient for diagnosing CVOI. A multidimensional diagnostic framework, integrating symptomatology, venographic morphology, and venous flow dynamics, is essential to improve diagnostic accuracy and guide individualized management. Recognizing the complexity of this condition may prevent underdiagnosis and optimize outcomes for patients with CVOI.
- 23 March 2026
- Published by Wolters Kluwer Health in Brain Circulation
- Vol. 12 (4) , 362-377
Open AccessRethinking the diagnostic criteria for cerebral venous outflow insufficiency: Is elevated intracranial pressure essential? A narrative review
The relationship between intracranial hypertension (IH) and cerebral venous outflow insufficiency (CVOI), including cerebral venous sinus stenosis (CVSS) and internal jugular vein stenosis (IJVS), remains controversial. Although elevated intracranial pressure (ICP) is often regarded as a hallmark of CVOI, recent evidence indicates that a subset of patients with radiologically confirmed CVSS or IJVS exhibit normal or only mildly elevated ICP (< 250 mmH 2 O). This challenges the notion that ICP elevation is essential for diagnosis and raises concern about misdiagnosis when relying solely on ICP thresholds. This review summarizes the clinical features, imaging findings, and hemodynamic characteristics of CVOI and examines the bidirectional relationship between CVOI and ICP. Possible mechanisms for normal ICP include preserved lymphatic cerebrospinal fluid drainage, collateral venous pathways, and anatomical variation. Moreover, persistent ICP elevation may itself cause secondary venous collapse, creating a feedback loop. These findings suggest that ICP elevation is neither necessary nor sufficient for diagnosing CVOI. A multidimensional diagnostic framework, integrating symptomatology, venographic morphology, and venous flow dynamics, is essential to improve diagnostic accuracy and guide individualized management. Recognizing the complexity of this condition may prevent underdiagnosis and optimize outcomes for patients with CVOI.
- Open Access
Cerebral Venous Outflow Insufficiency: A Study on Symptoms and Venous Stenosis Classification
Cerebral venous outflow insufficiency (CVOI) is a recently recognized cerebrovascular condition characterized by impaired venous drainage from the brain to the extracranial system. However, its clinical phenotypes and classification criteria remain poorly defined. In this single‐center cross‐sectional study, we analyzed 245 patients with CVOI using contrast‐enhanced CT or MR venography to identify clinical features and propose a novel anatomical classification. We identified 10 major symptoms of cerebral venous congestion, with tinnitus cerebri, neck discomfort, and tinnitus being the most common. A new classification system was proposed based on lesion location and bilateral jugular foramen narrowing rate, categorizing CVOI into intracranial (CV), extracranial (JV), and tandem (CJV) types, each further stratified into four/five subtypes. Receiver operating characteristic (ROC) curve analysis showed that narrowing thresholds of 0.20 and 0.40 offered excellent discriminatory performance for subtype differentiation, with an area under the curve (AUC) approaching 1.0. Notably, tandem‐type CVOI (CJV) was the most prevalent (56.7%) and exhibited distinct symptom patterns and pathogenesis. These findings provide a practical framework for diagnosing and stratifying CVOI and may inform individualized treatment strategies.
Open AccessCerebral Venous Outflow Insufficiency: A Study on Symptoms and Venous Stenosis Classification
Cerebral venous outflow insufficiency (CVOI) is a recently recognized cerebrovascular condition characterized by impaired venous drainage from the brain to the extracranial system. However, its clinical phenotypes and classification criteria remain poorly defined. In this single‐center cross‐sectional study, we analyzed 245 patients with CVOI using contrast‐enhanced CT or MR venography to identify clinical features and propose a novel anatomical classification. We identified 10 major symptoms of cerebral venous congestion, with tinnitus cerebri, neck discomfort, and tinnitus being the most common. A new classification system was proposed based on lesion location and bilateral jugular foramen narrowing rate, categorizing CVOI into intracranial (CV), extracranial (JV), and tandem (CJV) types, each further stratified into four/five subtypes. Receiver operating characteristic (ROC) curve analysis showed that narrowing thresholds of 0.20 and 0.40 offered excellent discriminatory performance for subtype differentiation, with an area under the curve (AUC) approaching 1.0. Notably, tandem‐type CVOI (CJV) was the most prevalent (56.7%) and exhibited distinct symptom patterns and pathogenesis. These findings provide a practical framework for diagnosing and stratifying CVOI and may inform individualized treatment strategies.
- Open Access
- 1 January 2026
- Published by Innovation Press Co., Limited in The Innovation Neurology
- Vol. 1 (1) , 100007-1-100007-3
Diagnosis and treatment of venous reflux disorders of head and neck
- 1 January 2026
- Published by Innovation Press Co., Limited in The Innovation Neurology
- Vol. 1 (1) , 100007-1-100007-3
Open AccessDiagnosis and treatment of venous reflux disorders of head and neck
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10)
Maintaining Balance: An Update on Nonpharmacological Cytoprotection Therapy for Acute Ischemic Stroke
Reperfusion therapies have become the standard of care for patients with acute ischemic stroke (AIS). However, around half of treated patients do not regain functional independence despite successful recanalization. Potentially avoidable unbalanced states that prevail both before and after reperfusion therapy might account for such unfavorable functional outcomes. They include energy supply versus energy demand in the ischemia phase, hypoperfusion versus hyperperfusion in the reperfusion phase, and acute cytotoxic versus prorepair inflammation in subacute and chronic stages. Classical pharmacological approaches only target one of these imbalances, which is insufficient. Nonpharmacological therapies are typically multitargets and have provided new evidence for benefit in AIS. This topical review discusses the latest evidence regarding nonpharmacological strategies for brain cytoprotection in AIS targeting the 3 above imbalances. We also focus on the mechanisms underlying the benefits of nonpharmacological therapies and present promising results from recent large-scale clinical trials testing them in AIS. We further elaborate on the prospects of several nonpharmacological brain protection strategies applied in the different AIS scenarios. By gaining a deeper understanding of the imbalanced states in AIS and the advantages of nonpharmacological brain cytoprotection therapies, future clinical trials may be further refined to translate nonpharmacological brain cytoprotection therapies to the clinic.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10)
Maintaining Balance: An Update on Nonpharmacological Cytoprotection Therapy for Acute Ischemic Stroke
Reperfusion therapies have become the standard of care for patients with acute ischemic stroke (AIS). However, around half of treated patients do not regain functional independence despite successful recanalization. Potentially avoidable unbalanced states that prevail both before and after reperfusion therapy might account for such unfavorable functional outcomes. They include energy supply versus energy demand in the ischemia phase, hypoperfusion versus hyperperfusion in the reperfusion phase, and acute cytotoxic versus prorepair inflammation in subacute and chronic stages. Classical pharmacological approaches only target one of these imbalances, which is insufficient. Nonpharmacological therapies are typically multitargets and have provided new evidence for benefit in AIS. This topical review discusses the latest evidence regarding nonpharmacological strategies for brain cytoprotection in AIS targeting the 3 above imbalances. We also focus on the mechanisms underlying the benefits of nonpharmacological therapies and present promising results from recent large-scale clinical trials testing them in AIS. We further elaborate on the prospects of several nonpharmacological brain protection strategies applied in the different AIS scenarios. By gaining a deeper understanding of the imbalanced states in AIS and the advantages of nonpharmacological brain cytoprotection therapies, future clinical trials may be further refined to translate nonpharmacological brain cytoprotection therapies to the clinic.
- 23 September 2025
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 53 (11) , 2856-2869
StrokeENDPredictor-19: Setting New Prediction Model in Neurological Prognosis in Acute Ischemic Stroke
Background and Purpose Early Neurological Deterioration (END) following intravenous thrombolysis (IVT) highlights potential risks in current management strategies for acute ischemic stroke. Early identification of at-risk patients could enhance treatment efficacy. This study aims to develop an advanced AI predictive model that improves accuracy in forecasting END while ensuring interpretability for clinical application. Methods This prospective cohort study included 970 patients with acute ischemic stroke who underwent IVT. Data from 365 patients were used for model development and internal validation, while data from 605 patients were utilized for external validation. Five machine learning models were developed and compared using evaluation metrics such as accuracy and AUC. Feature selection and model optimization were performed using the XGBoost algorithm and SHapley Additive exPlanations (SHAP) method, resulting in the StrokeENDPredictor-19 model. Results Among the five models, XGBoost demonstrated superior performance with an internal validation accuracy of 91% (AUC = 0.96) and external validation accuracy of 90% (AUC = 0.95). Notably, this study established cutoff values for critical clinical features, providing quantifiable reference standards for practical applications. Conclusion The StrokeENDPredictor-19 model offers neurologists a valuable tool for forecasting the likelihood of END in patients receiving IVT therapy, thereby supporting more precise clinical decision-making.
- 23 September 2025
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 53 (11) , 2856-2869
StrokeENDPredictor-19: Setting New Prediction Model in Neurological Prognosis in Acute Ischemic Stroke
Background and Purpose Early Neurological Deterioration (END) following intravenous thrombolysis (IVT) highlights potential risks in current management strategies for acute ischemic stroke. Early identification of at-risk patients could enhance treatment efficacy. This study aims to develop an advanced AI predictive model that improves accuracy in forecasting END while ensuring interpretability for clinical application. Methods This prospective cohort study included 970 patients with acute ischemic stroke who underwent IVT. Data from 365 patients were used for model development and internal validation, while data from 605 patients were utilized for external validation. Five machine learning models were developed and compared using evaluation metrics such as accuracy and AUC. Feature selection and model optimization were performed using the XGBoost algorithm and SHapley Additive exPlanations (SHAP) method, resulting in the StrokeENDPredictor-19 model. Results Among the five models, XGBoost demonstrated superior performance with an internal validation accuracy of 91% (AUC = 0.96) and external validation accuracy of 90% (AUC = 0.95). Notably, this study established cutoff values for critical clinical features, providing quantifiable reference standards for practical applications. Conclusion The StrokeENDPredictor-19 model offers neurologists a valuable tool for forecasting the likelihood of END in patients receiving IVT therapy, thereby supporting more precise clinical decision-making.
- Open Access
- 19 April 2025
- Published by Springer Nature in Cell & Bioscience
- Vol. 15 (1) , 1-14
Molecular mechanisms of endothelial–mesenchymal transition and its pathophysiological feature in cerebrovascular disease
The phenomenon of endothelial–mesenchymal transition (EndMT), a distinct subtype of epithelial–mesenchymal transition (EMT), has garnered significant attention from scholars. EndMT refers to the process whereby endothelial cells (ECs) transform into mesenchymal cells in response to various stimuli, resulting in the loss of their original characteristics. This process has diverse implications in both physiological and pathological states. Under physiological conditions, EndMT plays a crucial role in the development of the cardiovascular system. Conversely, under pathological conditions, EndMT has been identified as a pivotal factor in the development of cardiovascular diseases. Nonetheless, a comprehensive overview of EndMT in cerebrovascular disease is currently lacking. Here, we discuss the heterogeneity of EndMT occurrence and the regulatory factors involved in its development and analyze the feasibility of EndMT as a therapeutic target, aiming to provide a solid theoretical foundation and evidence to address diseases caused by pathological EndMT.
- 19 April 2025
- Published by Springer Nature in Cell & Bioscience
- Vol. 15 (1) , 1-14
Open AccessMolecular mechanisms of endothelial–mesenchymal transition and its pathophysiological feature in cerebrovascular disease
The phenomenon of endothelial–mesenchymal transition (EndMT), a distinct subtype of epithelial–mesenchymal transition (EMT), has garnered significant attention from scholars. EndMT refers to the process whereby endothelial cells (ECs) transform into mesenchymal cells in response to various stimuli, resulting in the loss of their original characteristics. This process has diverse implications in both physiological and pathological states. Under physiological conditions, EndMT plays a crucial role in the development of the cardiovascular system. Conversely, under pathological conditions, EndMT has been identified as a pivotal factor in the development of cardiovascular diseases. Nonetheless, a comprehensive overview of EndMT in cerebrovascular disease is currently lacking. Here, we discuss the heterogeneity of EndMT occurrence and the regulatory factors involved in its development and analyze the feasibility of EndMT as a therapeutic target, aiming to provide a solid theoretical foundation and evidence to address diseases caused by pathological EndMT.